上证指数开盘报3358.91点，跌0.10%。 深证成指开盘报10039.00点，跌0.13%。 创业板指开盘报2026.88点，涨0.00%。 沪深300开盘报3839.78点，跌0.09%。 科创50开盘报963.78点，涨0.09%。 中证500开盘报5669.09点，跌0.14%。 中证1000开盘报6039.99点，跌0.14%。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 | 成交额 | 年初至今 | | --- | --- | --- | --- | --- | --- | --- | | 000001 | 上证指数 | 3358.91 c | -3.20 | -0.10% | 28亿 | 0.21% | | 399001 | 深证成指 | 10039.00 c | -12.96 | -0.13% | 60亿 | -3.61% | | 899050 | 北证50 | 1360.40 c | -5.39 | -0.39% | 2.0亿 | 31.08% | | 881001 | 万得全A | 5099.70 c | -3.43 | -0.07% | 90亿 | 1.55% | | 0006 ...

Group 1 - The total trading volume of the ChiNext Index ETFs reached 1.641 billion yuan today, an increase of 456 million yuan from the previous trading day, representing a growth rate of 38.52% [1] - Specifically, the E Fund ChiNext ETF (159915) had a trading volume of 1.408 billion yuan today, up by 409 million yuan from the previous day, with a growth rate of 40.89% [1] - The GF ChiNext ETF (159952) recorded a trading volume of 93.2405 million yuan, an increase of 15.8598 million yuan, with a growth rate of 20.50% [1] Group 2 - The ChiNext Index (399006) closed down by 1.36%, while the average decline of related ETFs tracking the ChiNext Index was 1.26% today [1] - The ETFs with the largest trading volume increases included the CCB ChiNext ETF (159956) and the Harvest ChiNext Enhanced Strategy ETF (159675), which saw increases of 157.15% and 70.30%, respectively [1] - The top decliners among the ETFs included the Puyin Ansheng ChiNext ETF (159810) and the ChiNext ETF from ICBC (159958), which fell by 1.57% and 1.45%, respectively [1]

Core Viewpoint - The enthusiasm of investors in the pharmaceutical primary market has been reignited due to the China Securities Regulatory Commission's announcement of the "1+6" policy measures, which will support unprofitable innovative companies in listing on the Sci-Tech Innovation Board (STAR Market) [1][9]. Group 1: Policy Changes - The introduction of the "new fifth set" listing standards aims to provide a differentiated listing channel for innovative companies that are in the high R&D investment phase but have not yet achieved stable revenue [3][4]. - The "1" in the "1+6" policy refers to the establishment of a Sci-Tech Growth Layer on the STAR Market, which will include all existing and newly registered unprofitable technology companies [3]. - The fifth set of standards will expand its applicability beyond biomedicine to include sectors such as artificial intelligence, commercial aerospace, and low-altitude economy [7]. Group 2: Market Impact - The previous tightening of the STAR Market and the discounting of Hong Kong IPOs led to a significant reduction in investment activity in the pharmaceutical sector, but the reintroduction of the fifth set of standards is expected to enhance investment willingness and risk appetite in the primary market [1][2]. - Since the STAR Market's inception, 20 innovative biopharmaceutical companies have utilized the fifth set of standards for fundraising, with the total investment amount in the biopharmaceutical sector reaching a peak of $34 billion in 2021 [8]. - In 2022, the total investment in the domestic pharmaceutical industry dropped to $15.6 billion, halving compared to the previous year, and further decreased to $10.9 billion in 2023, marking a 30% year-on-year decline [8]. Group 3: Investor Sentiment - The new policies are expected to restore key listing channels for unprofitable pharmaceutical companies, thereby boosting investor confidence and attracting social capital into the biopharmaceutical sector [9]. - There are concerns about potential overheating in the market due to the execution of these policies and the resonance with market sentiment, which could lead to high valuations or share price declines for some unprofitable technology companies post-listing [9].

上证指数收报3362.11点，跌0.79%。 深证成指收报10051.97点，跌1.21%。 创业板指收报2026.82点，跌1.36%。 沪深300收报3843.09点，跌0.82%。 科创50收报962.94点，跌0.54%。 中证500收报5676.83点，跌1.20%。 中证1000收报6048.22点，跌1.42%。 ...

中国上证综指6月19日（周四）收盘下跌26.7点，跌幅：0.79%，报3362.11点； 中国深证成指6月19日（周四）收盘下跌123.62点，跌幅：1.21%，报10051.97点； 中国沪深300指数6月19日（周四）收盘下跌31.88点，跌幅：0.82%，报3843.09点； 中国创业板指数6月19日（周四）收盘下跌27.91点，跌幅：1.36%，报2026.82点； 中国科创50指数6月19日（周四）收盘下跌5.24点，跌幅：0.54%，报962.94点。 ...

A股午后持续下跌，三大股指均跌超1%，创业板指跌1.39%，深证成指跌1.25%，全市场超4700只个股 飘绿。 ...

暗盘资金正涌入这些股票，点击速看>>> A股午后持续走低，三大股指均跌超1%，创业板指跌1.39%，深证成指跌1.25%，全市场超4700只个股 飘绿。 ...

中国上证综指6月19日（周四）开盘下跌4.52点，跌幅：0.13%，报3384.29点； 中国深证成指6月19日（周四）开盘下跌19.41点，跌幅：0.19%，报10156.17点； 中国沪深300指数6月19日（周四）开盘下跌4.92点，跌幅：0.13%，报3870.05点； 中国创业板指数6月19日（周四）开盘下跌5.55点，跌幅：0.27%，报2049.18点； 中国科创50指数6月19日（周四）开盘下跌1.26点，跌幅：0.13%，报966.92点。 ...

A股开盘，沪指开跌0.13%，深证成指开跌0.19%，创业板指开跌0.27%，油气股回调。 ...

Core Viewpoint - The legal opinion issued by Shanghai Jintiancheng Law Firm confirms that Xinhenghui Electronics Co., Ltd. has met all necessary legal requirements for its initial public offering (IPO) and listing on the ChiNext board, including internal approvals and regulatory compliance [1][4][9]. Group 1: Approval and Authorization - The company held its annual general meeting on April 29, 2022, where it approved the proposal for the IPO, with the resolution valid for 12 months until April 28, 2023, and subsequently extended to April 28, 2026 [4][5]. - The Shenzhen Stock Exchange's Listing Review Committee approved the company's IPO application on March 22, 2023 [5]. - The China Securities Regulatory Commission (CSRC) granted approval for the IPO registration on March 18, 2025, valid for 12 months [5]. - The Shenzhen Stock Exchange issued a notice on June 18, 2025, allowing the company's shares to be listed on the ChiNext board under the stock code "301678" [5]. Group 2: Company Qualifications - The company holds a valid business license issued by the Zibo Administrative Approval Service Bureau, confirming its legal existence and operational status [6]. - Xinhenghui Electronics was established as a joint-stock company through a restructuring process in November 2020 and has been operating for over three years [6]. Group 3: Substantive Conditions for IPO - The IPO has received the necessary approval from the CSRC, meeting the requirements set forth in the Securities Law and the ChiNext Listing Rules [6][9]. - The company's total share capital before the IPO was RMB 179.666 million, which increased to RMB 239.555467 million post-IPO, exceeding the minimum requirement of RMB 30 million [7]. - The company issued 59.888867 million shares in the IPO, representing over 25% of the total shares post-IPO [7]. - The company reported net profits for the years 2023 and 2024, meeting the requirement of positive net profits for the last two years and a cumulative net profit of no less than RMB 50 million [8]. - The company's directors, supervisors, and senior management have made commitments regarding the accuracy and completeness of the IPO application documents [8]. Group 4: Sponsorship and Commitments - The company has appointed Founder Securities as the sponsor for the IPO, which is registered with the CSRC and has membership with the Shenzhen Stock Exchange [9]. - The company and its major stakeholders have made public commitments regarding the IPO, including measures for accountability in case of non-compliance [9].